Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipase Thera-blend + tributyrin is a combination product containing **lipase enzymes** (derived from Candida rugosa and Rhizopus oryzae) and **tributyrin**, a triglyceride prodrug of butyric acid (butyrate)[2]. Lipase Thera-blend provides enzyme replacement to aid the digestion of fats, while tributyrin serves as a source of butyrate, a short-chain fatty acid linked to gut and metabolic health[2][4]. Tributyrin must be hydrolyzed by lipase to release butyrate, making the combination relevant for efficient delivery and absorption of butyrate. The primary indications involve supporting memory and cognitive function in adults with self-reported memory problems, and potentially aiding in digestive health[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lipase Thera-blend + tributyrin.